Kabi Pens Agreement To Launch Generic Exparel In 2030 – With A Volume Limit
German Firm And Partner Jiangsu Hengrui Face Near Decade Of Cap On Volumes
With sales of $550m last year and a high barrier to entry, Exparel marks an intriguing target for abbreviated new drug application sponsors. Having shot down a US patent last year and won US FDA approval for its ANDA, Jiangsu Hengrui’s US eVenus Pharmaceutical Laboratories subsidiary and partner Fresenius Kabi have just reached a settlement agreement.
